🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Haemonetics Corporation HAE R2K

Healthcare · Medical Devices · United States
https://www.haemonetics.com

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

READ MORE ›
$67.81
+0.15% 1Y

Market & Price

Market Cap
$3.08B
Current Price
$67.81
High / Low (52W)
$87.16 / $47.67
Beta
0.53

Valuation

Stock P/E
33.08
Industry PE
23.65
Forward P/E
11.76
PEG Ratio
1.08
Book Value
$19.46
Price to Book
3.48
P/S
2.31
EV/EBITDA
11.51
Dividend Yield
-

Profitability & Returns

ROCE
7.42%
ROE
12.03%
ROA
6.49%
Profit Margin
7.29%
Op Margin
13.88%
EPS (Latest Qtr)
$0.95
EPS (TTM)
$2.05

Balance Sheet & Liquidity

Debt/Equity
1.60
Quick Ratio
1.64
Current Ratio
2.95
Debt
$1.27B
Total Assets
$2.40B
Current Assets
$834.88M
Working Capital
$552.28M

Ownership

Promoter Holding
1.61%
Chg in Prom Hold
-
FII / Inst Holding
107.98%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$4.11B
Total Revenue (TTM)
$1.33B
EBITDA
$357.15M
Free Cash Flow
$298.09M
Operating Cash Flow
$293.22M
Shares Outstanding
45.45M
Gross Margin
59.43%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
4.51%
Profit 5Y
-5.53%
Revenue (YoY)
4.80%
Earnings (YoY)
-

PROS

  • Generates positive free cash flow.

CONS

  • Earnings shrank at -5.5% CAGR over 5 years.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 HAE Haemonetics Corporation R2K 67.81 33.08 $3.08B - 7.42% 12.03% 4.51% -5.53%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Apr 2016Jul 2016Oct 2016Dec 2016Apr 2017Jul 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Apr 2021Jul 2021Oct 2021Jan 2022Jul 2022Oct 2022Dec 2022Jul 2023Sep 2023Dec 2023Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------210.95M225.38M234.04M-229.35M241.58M247.36M-238.45M252.57M258.97M-195.58M209.49M240.37M-228.53M239.90M259.77M261.46M297.49M305.30M311.33M318.18M336.25M336.17M345.51M-330.60M321.39M327.31M338.97M346.35M
Cost of Revenue -----------------------------------137.55M129.15M132.57M136.58M148.14M
Gross Profit 105.30M108.86M89.22M91.06M104.25M101.08M82.11M91.67M104.56M111.30M104.39M83.24M111.91M111.17M111.21M115.91M127.00M128.05M113.56M90.03M105.74M120.26M81.81M108.08M122.54M138.56M142.26M157.88M158.71M167.26M170.51M177.87M174.92M187.44M-193.05M192.24M194.74M202.39M198.21M
Operating Expenses -----------------------------------142.35M138.37M127.67M134.27M145.87M
Operating Income 19.18M-61.18M-5.55M-7.88M24.79M21.21M-57.51M16.61M24.26M1.01M14.28M5.29M26.08M28.32M23.86M-13.30M49.74M40.91M26.01M11.71M58.78M40.42M-21.18M1.39M24.51M35.65M30.77M46.73M43.28M53.66M35.30M45.98M39.76M51.70M-50.70M53.87M67.08M68.11M52.34M
EBITDA -----------------------------------99.54M82.63M86.75M94.78M4.29M
Interest Expense -----------------------------------598.00K8.70M7.21M7.42M5.37M
Pretax Income -----------------------------------70.74M45.17M51.28M59.98M-28.40M
Tax Provision -----------------------------------12.76M11.14M12.60M15.23M-8.25M
Net Income 12.86M-59.44M-8.73M-10.35M19.82M15.39M-51.14M20.14M20.10M-6.55M11.88M-2.82M18.73M-8.48M20.84M-8.48M37.49M29.89M17.62M10.53M48.10M31.88M-11.04M-4.45M14.86M23.23M19.88M33.20M32.94M41.04M24.91M31.24M38.37M33.83M-57.98M34.03M38.68M44.74M-20.15M
Diluted EPS 0.25-1.17-0.17-0.200.380.30-0.980.380.38-0.120.22-0.050.350.350.40-0.170.720.580.340.210.940.62-0.22-0.090.290.450.380.640.640.800.480.610.740.660.741.170.700.810.95-
R&D Expense 11.55M10.94M-11.44M8.34M8.46M-8.19M7.52M12.43M-9.41M8.58M8.98M-7.49M7.42M7.00M-7.75M6.76M7.50M-12.70M10.85M10.04M10.90M10.90M12.69M12.65M12.66M13.27M14.45M14.14M15.83M-16.26M14.87M14.19M-

Profit & Loss (Annual)

Figures in USD.

Metric Mar 2009Apr 2010Apr 2011Mar 2012Mar 2013Mar 2014Mar 2015Apr 2016Apr 2017Mar 2018Mar 2019Mar 2020Apr 2021Mar 2022Apr 2022Mar 2023Apr 2023Mar 2024Mar 2025Mar 2026
Revenue --------------993.20M1.17B1.17B1.31B1.36B1.33B
Cost of Revenue ---------------553.56M-617.51M611.87M546.44M
Gross Profit 308.17M337.48M355.21M369.24M428.13M468.37M434.42M405.91M378.49M411.91M417.54M484.51M397.84M-505.50M615.10M615.10M691.55M748.96M787.59M
Operating Expenses ---------------459.45M-516.25M547.77M546.18M
Operating Income 85.57M83.28M110.55M88.76M56.44M46.43M40.54M-43.94M-19.38M56.16M83.55M103.35M89.75M-80.75M155.65M156.03M175.30M201.19M241.40M
EBITDA ---------------249.34M-262.10M337.40M268.45M
Interest Expense ---------------14.63M-13.02M9.75M28.70M
Pretax Income ---------------141.40M-151.87M212.07M128.03M
Tax Provision ---------------26.00M-34.31M44.39M30.72M
Net Income 59.30M58.37M79.98M66.89M38.80M35.15M16.90M-55.58M-26.27M45.57M55.02M76.53M79.47M-43.38M115.40M115.40M117.56M167.68M97.31M
Diluted EPS 2.272.241.561.300.740.670.32-1.09-0.510.851.041.481.550.840.842.242.242.293.31-
R&D Expense 23.86M26.38M32.66M36.80M44.39M54.20M54.19M44.97M37.56M39.23M35.71M30.88M32.86M-46.80M-50.13M54.44M62.72M59.77M

Compounded Sales Growth

5 Years:4.51%
1 Year:4.80%

Compounded Profit Growth

5 Years:-5.53%
1 Year:-

Stock Price Performance

1 Year:+0.15%
6 Months:-15.90%
3 Months:+7.09%
1 Month:+14.91%

Balance Sheet (Annual)

Figures in USD.

Metric Mar 2008Mar 2009Apr 2010Apr 2011Mar 2012Mar 2013Mar 2014Mar 2015Apr 2016Apr 2017Mar 2018Mar 2019Mar 2020Apr 2021Mar 2022Apr 2022Mar 2023Apr 2023Mar 2024Mar 2025Mar 2026
Total Assets --764.30M833.26M911.13M1.46B1.51B1.49B1.32B1.24B1.24B1.27B1.27B1.82B-1.86B1.93B1.93B2.20B2.45B2.40B
Current Assets ----------------769.72M-768.90M934.98M834.88M
Cash & Equivalents 133.55M156.72M141.56M196.71M228.86M179.12M192.47M160.66M115.12M139.56M180.17M169.35M137.31M192.31M-259.50M284.47M284.47M178.80M306.76M245.44M
Inventory ----------------259.38M-317.20M365.14M306.37M
Receivables ----------------179.14M-206.56M202.66M216.85M
Total Liabilities ----------------1.12B-1.24B1.63B1.60B
Current Liabilities --135.05M108.67M130.74M180.14M216.93M188.68M185.55M211.18M384.70M235.76M274.82M253.50M-442.27M251.82M251.82M300.38M578.11M282.60M
Long Term Debt --4.46M3.97M2.88M456.94M392.06M406.37M364.53M253.62M59.42M322.45M305.51M690.59M-559.44M754.10M754.10M797.56M921.23M1.22B
Total Debt ----------------765.89M-807.79M1.22B1.22B
Total Equity 494.19M539.88M593.12M686.14M732.63M769.18M837.89M826.12M721.57M739.61M752.43M667.87M587.11M731.67M-749.42M818.00M818.00M959.96M820.84M796.32M
Shares Outstanding ----------------50.45M-50.79M48.22M45.25M

Cash Flows (Annual)

Figures in USD.

Metric Mar 2009Apr 2010Apr 2011Mar 2012Mar 2013Mar 2014Mar 2015Apr 2016Apr 2017Mar 2018Mar 2019Mar 2020Apr 2021Mar 2022Apr 2022Mar 2023Apr 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 116.36M130.67M123.45M115.32M85.07M139.52M127.18M121.86M159.74M220.35M159.28M158.22M108.81M-172.26M273.06M273.06M181.75M181.72M293.22M
Investing Cash Flow -60.00M-132.34M-51.56M-52.20M-596.39M-105.83M-121.77M-104.77M-73.31M-63.04M-116.15M-57.18M-425.44M--86.34M-143.79M-143.79M-322.39M-161.90M-179.55M
Financing Cash Flow -30.74M-13.97M-18.08M-30.47M461.85M-20.70M-33.16M-62.62M-60.41M-120.64M-50.63M-131.21M367.45M--15.75M-100.36M-100.36M38.16M108.82M-178.46M
Capital Expenditure -56.38M-56.30M-46.67M-53.20M-62.19M-73.65M-122.22M-102.41M-76.14M-74.80M-118.96M-48.76M-37.04M--96.51M-191.33M-191.33M-38.12M-39.28M-32.78M
Free Cash Flow 59.98M74.36M76.79M62.12M22.89M65.88M4.96M19.46M83.60M145.55M40.32M109.46M71.77M-75.75M81.73M81.73M143.63M142.45M260.44M
Net Change in Cash ---------------28.91M--102.48M128.65M-64.79M
Share Buybacks 60.00M40.00M50.00M50.00M50.00M039.03M60.98M0100.00M160.00M175.00M0-0-75.00M0225.00M175.00M

Ratios (Annual)

Figures in %.

Metric Mar 2009Apr 2010Apr 2011Mar 2012Mar 2013Mar 2014Mar 2015Apr 2016Apr 2017Mar 2018Mar 2019Mar 2020Apr 2021Mar 2022Apr 2022Mar 2023Apr 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------------50.9%52.6%52.6%52.8%55.0%59.0%
Operating Margin % --------------8.1%13.3%13.4%13.4%14.8%18.1%
Net Margin % --------------4.4%9.9%9.9%9.0%12.3%7.3%
ROE % 11.0%9.8%11.7%9.1%5.0%4.2%2.0%-7.7%-3.6%6.1%8.2%13.0%10.9%-5.8%14.1%14.1%12.2%20.4%12.2%
ROCE % -13.2%15.3%11.4%4.4%3.6%3.1%-3.9%-1.9%6.6%8.0%10.4%5.7%-5.7%9.2%9.3%9.2%10.7%11.4%

Shareholding Pattern

Insiders
1.61%
Institutions
107.98%
Public Float
109.75%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 12.37% 5.62M $381.09M
2 Neuberger Berman Group, LLC 7.84% 3.56M $241.47M
3 AQR Capital Management, LLC 7.39% 3.36M $227.61M
4 Vanguard Portfolio Management LLC 5.63% 2.56M $173.55M
5 Vanguard Capital Management LLC 4.60% 2.09M $141.75M
6 State Street Corporation 3.90% 1.77M $120.22M
7 Arrowstreet Capital, Limited Partnership 3.04% 1.38M $93.78M
8 River Road Asset Management, LLC 2.92% 1.33M $90.05M
9 Dimensional Fund Advisors LP 2.92% 1.33M $89.92M
10 FMR, LLC 2.81% 1.28M $86.52M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HAE

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks